The humoral immune system monitors and regulates human health via antibodies.
The vast repertoire of antibodies represents the immune response to antigens including viruses, bacteria and allergens, as well as diseases including cancers, neurological, autoimmune, infectious and inflammatory diseases.
IPDx proprietary technology translates the intricate collection of antibodies into actionable data to develop diagnostics that help detect disease earlier and guide treatment decisions.
Our core technology Mimotope Variation analysis (MVA) combines random peptide phage display library screening, next-generation sequencing, and big data analytics to decode antibody signatures.
Antibody screening. Biological samples (blood, urine, saliva etc.) containing antibodies are screened against peptide phage display library containing 1010 peptides, mimicking the billions of naturally occurring antigens. Phage DNA encoding the displayed peptide sequence is isolated from antibody bound phages and sequenced to identify the antibody bound epitope peptides.
Data analysis. Epitope peptide sequences are analyzed using advanced computational methods to identify disease-specific epitope/mimotope sequences and sequence motifs. The disease-specific epitope peptides and motifs may represent both antigens of functional antibodies involved in disease-causing pathways and antibodies that reflect downstream pathway changes related to the disease.
Our understanding of the antibody repertoire is ever growing with each MVA analysis. Every consecutive analysis is added to our database enhancing the computational power of MVA and delivering further insight into disease mechanisms.
Diagnostics. Leveraging the disease-specific peptides we can develop diagnostics to reveal antibody signatures that represent a variety of diseases including cancers, autoimmune, neurological, infectious and inflammatory diseases.
IPDx collaborates with partners interested in:
Collaborators include academia, biopharma, and healthcare companies.
Contact us to hear more
IPDx, in 2016, was awarded a grant from Sächsische Aufbaubank to develop multi-biomarker point of care tests targeting different types of cancer.
IPDx Diagnostics OÜ‘s project (EU53347) „Preliminary studies for ImmunoHealth diagnostics service
platform“ is supported by Norway Grants Green ICT small scheme programme, aiming to stimulate and
develop innovation-led long-term business cooperation between Estonia and Norway. The small scheme
project is necessary to prepare for the main call project in order to develop a solution ImmunoHealth
that enables to predict type 2 diabetes in early stage by utilizing immunoprofiling based disease and
health risk diagnostics solution. Green ICT small scheme project is necessary to assess feasibility of the
project, map certification requirements, carry out business studies and put together development plan
for the platform. The implementation period is 01.07.2019 – 31.10.2019.
IPDx joined the EIT health network in 2019 and we are currently finalist in the 2019 European health catapult program.
IPDx has been granted the SME instrument to further illustrate the symbiosis between the microbiome and immunome. With this project we will demonstrate how to easily monitor changes of the microbiome via antibody profiles while also being able to influence microbiome compositions.